☆ 4.7 Meeting Abstract

Neoadjuvant mFOLFIRINOX and preoperative chemoradiation (CRT) versus preoperative CRT in patients with T3-4 rectal cancer: Surgical and quality of life results of PRODIGE 23 phase III trial

ANNALS OF ONCOLOGY (2020)

Journal

ANNALS OF ONCOLOGY

Volume 31, Issue -, Pages S1152-S1152

Publisher

ELSEVIER

DOI: 10.1016/j.annonc.2020.08.2249

Keywords

-

Categories

Oncology

Funding

French National Cancer Institute
French National League Against Cancer

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23) : a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy, Jean-Francois Bosset, Pierre-Luc Etienne, Emmanuel Rio, Eric Francois, Nathalie Mesgouez-Nebout, Veronique Vendrely, Xavier Artignan, Olivier Bouche, Dany Gargot, Valerie Boige, Nathalie Bonichon-Lamichhane, Christophe Louvet, Clotilde Morand, Christelle de la Fouchardiere, Najib Lamfichekh, Beata Juzyna, Claire Jouffroy-Zeller, Eric Rullier, Frederic Marchal, Sophie Gourgou, Florence Castan, Christophe Borg

Summary: In patients with cT3 or cT4 M0 rectal cancer, intensifying chemotherapy with FOLFIRINOX before preoperative chemoradiotherapy significantly improved disease-free survival outcomes and reduced neurotoxicity. Thus, the PRODIGE 23 results have the potential to impact clinical practice.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis

Caroline Bascoul-Mollevi, Sophie Gourgou, Christophe Borg, Pierre-Luc Etienne, Emmanuel Rio, Eric Rullier, Beata Juzyna, Florence Castan, Thierry Conroy

Summary: Results from the PRODIGE 23 study showed that neoadjuvant chemotherapy (NAC) with mFOLFIRINOX and preoperative chemoradiotherapy improved disease-free survival in patients with locally advanced rectal cancer. This study aimed to assess the impact of this treatment on health-related quality of life (HRQOL) outcomes.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Review Oncology

Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials

E. F. Giunta, G. Bregni, A. Pretta, A. Deleporte, G. Liberale, A. M. Bali, L. Moretti, T. Troiani, F. Ciardiello, A. Hendlisz, F. Sclafani

Summary: The results from two randomized phase III trials of total neoadjuvant therapy (TNT) in locally advanced rectal cancer consistently show better outcomes compared to standard neoadjuvant treatments, providing support for the use of TNT in clinical practice. However, significant differences between these trials present challenges for generalizability and practical recommendations, highlighting the need for further investigation and research.

CANCER TREATMENT REVIEWS (2021)

Add to Collection

Article Oncology

Avoiding Unnecessary Major Rectal Cancer Surgery by Implementing Structural Restaging and a Watch-and-Wait Strategy After Neoadjuvant Radiochemotherapy

J. F. Huisman, I. J. H. Schoenaker, R. M. Brohet, O. Reerink, H. van der Sluis, F. C. P. Moll, E. de Boer, J. C. de Graaf, W. H. de Vos tot Nederveen Cappel, G. L. Beets, H. L. van Westreenen

Summary: The study demonstrates that the introduction of structured multidisciplinary response evaluation leads to a significant decrease in patients with locally advanced rectal cancer achieving complete response after nCRT, reducing the need for surgery and improving stoma-free survival rates.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Clinical outcome of neoadjuvant chemoradiation in rectal cancer treatment

Weerapat Suwanthanma, Saowanee Kitudomrat, Chakrapan Euanorasetr

Summary: The study investigated the clinical and pathological outcomes of locally advanced rectal cancer patients treated with neoadjuvant chemoradiation followed by curative surgery, identifying tumor length and lymph node involvement as potential predictive factors for pathological complete response. Patients achieving pCR showed higher 5-year disease-free and overall survival rates compared to non-pCR patients.

MEDICINE (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Response prediction of neoadjuvant chemoradiation therapy in locally advanced rectal cancer using CT-based fractal dimension analysis

Toru Tochigi, Sophia C. Kamran, Anushri Parakh, Yoshifumi Noda, Balaji Ganeshan, Lawrence S. Blaszkowsky, David P. Ryan, Jill N. Allen, David L. Berger, Jennifer Y. Wo, Theodore S. Hong, Avinash Kambadakone

Summary: This study assessed the use of CT-based fractal dimension and texture analysis in predicting the therapeutic response to nCRT in patients with locally advanced rectal cancer. The research found that fractal dimension was a significant parameter for predicting the efficacy of nCRT.

EUROPEAN RADIOLOGY (2022)

Add to Collection

Article Oncology

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy

Julio Garcia-Aguilar, Sujata Patil, Marc J. Gollub, Jin K. Kim, Jonathan B. Yuval, Hannah M. Thompson, Floris S. Verheij, Dana M. Omer, Meghan Lee, Richard F. Dunne, Jorge Marcet, Peter Cataldo, Blase Polite, Daniel O. Herzig, David Liska, Samuel Oommen, Charles M. Friel, Charles Ternent, Andrew L. Coveler, Steven Hunt, Anita Gregory, Madhulika G. Varma, Brian L. Bello, Joseph C. Carmichael, John Krauss, Ana Gleisner, Philip B. Paty, Martin R. Weiser, Garrett M. Nash, Emmanouil Pappou, Jose G. Guillem, Larissa Temple, Iris H. Wei, Maria Widmar, Sabrina Lin, Neil H. Segal, Andrea Cercek, Rona Yaeger, J. Joshua Smith, Karyn A. Goodman, Abraham J. Wu, Leonard B. Saltz

Summary: This study demonstrates that organ preservation is achievable in patients with locally advanced rectal cancer treated with total neoadjuvant therapy, without a decrease in survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Neoadjuvant Chemoradiation Combined with Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer

Oliver J. Ott, Cihan Gani, Lars H. Lindner, Manfred Schmidt, Ulf Lamprecht, Sultan Abdel-Rahman, Axel Hinke, Thomas Weissmann, Arndt Hartmann, Rolf D. Issels, Daniel Zips, Claus Belka, Robert Grutzmann, Rainer Fietkau

Summary: The HyRec trial evaluated an intensified neoadjuvant and multimodality treatment schedule for locally recurrent rectal cancer patients, showing promising efficacy and high feasibility, with comparable toxicities and very high pathologically confirmed complete remission rates.

CANCERS (2021)

Add to Collection

Review Oncology

Radiotherapy in the preoperative neoadjuvant treatment of locally advanced rectal cancer

Zhen Yu, Yuying Hao, Yuhua Huang, Ling Ling, Xigang Hu, Simiao Qiao

Summary: Radiotherapy and chemotherapy are effective treatments for locally advanced rectal cancer. New neoadjuvant treatment options need to be explored for better outcomes. Targeted drugs and immunologic agents have shown efficacy in advanced rectal cancer but have not been commonly used in neoadjuvant therapy for LARC patients.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Surgery

Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial

Wei-Jian Mei, Xiao-Zhong Wang, Yun-Feng Li, Yue-Ming Sun, Chun-Kang Yang, Jun-Zhong Lin, Zu-Guang Wu, Rui Zhang, Wei Wang, Yong Li, Ye-Zhong Zhuang, Jian Lei, Xiang-Bin Wan, Ying-Kun Ren, Yong Cheng, Wen-Liang Li, Zi-Qiang Wang, Dong-Bo Xu, Xian-Wei Mo, Hai-Xing Ju, Sheng-Wei Ye, Jing-Lin Zhao, Hong Zhang, Yuan-Hong Gao, Zhi-Fan Zeng, Wei-Wei Xiao, Xiao-Peng Zhang, Xuan Zhang, E. Xie, Yi-Fei Feng, Jing-Hua Tang, Xiao-Jun Wu, Gong Chen, Li-Ren Li, Zhen-Hai Lu, De-Sen Wan, Jin-Xin Bei, Zhi-Zhong Pan, Pei-Rong Ding

Summary: This study compared the efficacy of neoadjuvant chemotherapy alone and neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. The results showed that neoadjuvant chemotherapy achieved similar rates of pathological complete response and downstaging compared to neoadjuvant chemoradiotherapy, but with lower incidence of perioperative distant metastasis and preventive ileostomy. CAPOX could be an effective alternative treatment option for patients with locally advanced rectal cancer.

ANNALS OF SURGERY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Biomarkers for Predicting the Response to Radiation-Based Neoadjuvant Therapy in Rectal Cancer

Yuhong Chen, Biao Yang, Mingyang Chen, Zhaojun Li, Zhengyin Liao

Summary: This article summarizes potential predictors of the therapeutic response of RC to nCRT, including biomarkers associated with genes, RNA, proteins, immune and tumor microenvironment-related biomarkers, imaging biomarkers, microbiome-associated biomarkers, and blood-based biomarkers.

FRONTIERS IN BIOSCIENCE-LANDMARK (2022)

Add to Collection

Article Oncology

A universal cell-free DNA approach for response prediction to preoperative chemoradiation in rectal cancer

Albert Grinshpun, Anatoli Kustanovich, Daniel Neiman, Roni Lehmann-Werman, Aviad Zick, Karen Meir, Elez Vainer, Roy Z. Granit, Amit Arad, Noa Daskal, Ruth Schwartz, Eli Sapir, Myriam Maoz, Esther Tahover, Joshua Moss, Iddo Z. Ben-Dov, Tamar Peretz, Ayala Hubert, Ruth Shemer, Yuval Dor

Summary: The standard treatment approach for stage II/III rectal cancer is neoadjuvant chemoradiation therapy followed by surgery. However, better tools are still needed to personalize therapy for the individual patient. In this study, the researchers analyzed colon-derived cell-free DNA using a tissue-specific DNA methylation signature and found that it can predict treatment outcomes and help guide patient selection strategies.

INTERNATIONAL JOURNAL OF CANCER (2023)

Add to Collection

Article Multidisciplinary Sciences

Clinical prediction model of pathological response following neoadjuvant chemoradiotherapy for rectal cancer

Jung Kyong Shin, Jung Wook Huh, Woo Yong Lee, Seong Hyeon Yun, Hee Cheol Kim, Yong Beom Cho, Yoon Ah Park

Summary: This study analyzed the predictive factors, recurrence patterns, oncologic outcomes, and prognostic factors of patients with pathologic complete response (pCR) in rectal cancer who underwent radical surgery after neoadjuvant chemoradiotherapy (nCRT). The study found that clinical node negativity, tumor size < 4 cm, and well differentiation were significant independent clinical predictors for achieving pCR. Patients with pCR had better long-term outcomes compared to those without pCR.

SCIENTIFIC REPORTS (2022)

Add to Collection

Article Oncology

MRI radiomics independent of clinical baseline characteristics and neoadjuvant treatment modalities predicts response to neoadjuvant therapy in rectal cancer

Maxiaowei Song, Shuai Li, Hongzhi Wang, Ke Hu, Fengwei Wang, Huajing Teng, Zhi Wang, Jin Liu, Angela Y. Jia, Yong Cai, Yongheng Li, Xianggao Zhu, Jianhao Geng, Yangzi Zhang, XiangBo Wan, Weihu Wang

Summary: This study aimed to analyze the performance of multicentre pre-treatment MRI-based radiomics (MBR) signatures combined with clinical baseline characteristics and neoadjuvant treatment modalities in predicting complete response to neoadjuvant (chemo)radiotherapy in locally advanced rectal cancer (LARC). The results showed that the radiomics-based models outperformed the non-imaging models, accurately reflecting the true nature of LARC and helping to identify patients who can undergo organ preservation strategies.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer

Huajing Teng, Yan Wang, Xin Sui, Jiawen Fan, Shuai Li, Xiao Lei, Chen Shi, Wei Sun, Maxiaowei Song, Hongzhi Wang, Dezuo Dong, Jianhao Geng, Yangzi Zhang, Xianggao Zhu, Yong Cai, Yongheng Li, Bo Li, Qingjie Min, Weihu Wang, Qimin Zhan

Summary: Preoperative neoadjuvant chemoradiotherapy (nCRT) is a standard treatment for locally advanced rectal cancer (LARC) patients, yet little is known about the mediators underlying the heterogeneous patient response. In this study, the researchers conducted 16S rRNA sequencing on fecal specimens from LARC patients and discovered a decrease in microbial diversity after nCRT. They also found that Bacteroides vulgatus-mediated nucleotide biosynthesis is associated with nCRT resistance, and nonrespon-sive tumors have upregulated genes related to DNA repair and nucleoside trans-port. Additionally, the researchers identified uric acid as a potential prognosis marker for LARC patients receiving nCRT.

CANCER CELL (2023)

Add to Collection

Article Oncology

BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer

William Jacot, Evelyne Lopez-Crapez, Caroline Mollevi, Florence Boissiere-Michot, Joelle Simony-Lafontaine, Alexandre Ho-Pun-Cheung, Elodie Chartron, Charles Theillet, Antoinette Lemoine, Raphael Saffroy, Pierre-Jean Lamy, Severine Guiu

CANCERS (2020)

Add to Collection

Article Oncology

Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival

Hanane Mansouri, Lindsay B. Alcaraz, Caroline Mollevi, Aude Mallavialle, William Jacot, Florence Boissiere-Michot, Joelle Simony-Lafontaine, Valerie Laurent-Matha, Pascal Roger, Emmanuelle Liaudet-Coopman, Severine Guiu

CANCERS (2020)

Add to Collection

Article Medical Informatics

GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials

D. Dinart, J. Fraisse, D. Tosi, A. Mauguen, C. Touraine, S. Gourgou, M. C. Le Deley, C. Bellera, C. Mollevi

BMC MEDICAL INFORMATICS AND DECISION MAKING (2020)

Add to Collection

Article Oncology

PhaseIIstudy evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE1)

Eric Assenat, Laurent Mineur, Caroline Mollevi, Evelyne Lopez-Crapez, Catherine Lombard-Bohas, Emmanuelle Samalin, Fabienne Portales, Thomas Walter, Helene de Forges, Marie Dupuy, Florence Boissiere-Michot, Alexandre Ho-Pun-Cheung, Marc Ychou, Thibaut Mazard

Summary: The combination of gemcitabine, trastuzumab, and erlotinib showed promising efficacy in terms of disease control, progression-free survival (PFS), and overall survival (OS) for patients with metastatic pancreatic cancer. The treatment was well tolerated with manageable toxicities, suggesting the need for further evaluation in a larger study comparing it to the standard regimen.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Article Health Care Sciences & Services

Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results

Caroline Bascoul-Mollevi, Antoine Barbieri, Celine Bourgier, Thierry Conroy, Bruno Chauffert, Mohamed Hebbar, William Jacot, Beata Juzyna, Helene De Forges, Sophie Gourgou, Franck Bonnetain, Celia Touraine, Amelie Anota

Summary: This study evaluated longitudinal analysis methods for HRQoL data in cancer clinical trials, finding concordant results between LMM and LPCM, while discordant results were observed with the TTD/TUDD method compared to the other two. According to methodological and practical arguments discussed, these methods seem to provide additional information and complementary interpretations.

QUALITY OF LIFE RESEARCH (2021)

Add to Collection

Review Oncology

Optimal biological dose: a systematic review in cancer phase I clinical trials

J. Fraisse, D. Dinart, D. Tosi, C. Bellera, C. Mollevi

Summary: This article summarizes research on early phase cancer clinical trials relying on the concept of optimal biological dose (OBD). Through a systematic review of 37 articles, the results show that most trials considered both efficacy and toxicity in defining OBD.

BMC CANCER (2021)

Add to Collection

Article Oncology

Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer

Florence Boissiere-Michot, Ghita Chabab, Caroline Mollevi, Severine Guiu, Evelyne Lopez-Crapez, Jeanne Ramos, Nathalie Bonnefoy, Virginie Lafont, William Jacot

Summary: The study revealed that high gamma delta T cell density was significantly associated with younger age, higher tumor grade, adjuvant chemotherapy, BRCA1 promoter methylation, TIL density, and PD-L1/PD-1 expression in triple-negative breast cancer patients, and served as an independent prognostic factor, especially in those with wild-type PIK3CA tumors.

CANCERS (2021)

Add to Collection

Article Oncology

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer

Antoine Adenis, Thibault Mazard, Julien Fraisse, Patrick Chalbos, Brice Pastor, Ludovic Evesque, Francois Ghiringhelli, Caroline Mollevi, Stephanie Delaine, Marc Ychou

Summary: This study aims to evaluate the safety and efficacy of regorafenib in combination with FOLFIRINOX as frontline therapy for patients with RAS-mutated metastatic colorectal cancer, representing the first trial of its kind. The research includes a dose-finding phase 1-2 trial with primary endpoints including determination of maximum tolerated dose, recommended dose, and proportion of patients achieving disease control at 48 weeks.

BMC CANCER (2021)

Add to Collection

Article Oncology

CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers

Florence Boissiere-Michot, William Jacot, Oceane Massol, Caroline Mollevi, Gwendal Lazennec

Summary: This study focused on the expression of CXCR2 in TNBC and its association with tumor characteristics and immune infiltration. High levels of CXCR2 were found to be correlated with better prognosis in a subgroup of TNBC patients.

CANCERS (2021)

Add to Collection

Article Oncology

Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer

Amelie Darlix, Christophe Hirtz, Caroline Mollevi, Nelly Ginestet, Laurent Tiers, William Jacot, Sylvain Lehmann

Summary: In patients with metastatic breast cancer, elevated serum levels of GFAP are independently associated with the presence of brain metastases and poor outcomes, outperforming other biomarkers such as NfL, UCHL1, and tau. These findings suggest that GFAP may serve as a valuable diagnostic and prognostic factor for brain metastases in this patient population, although further validation in independent cohorts is necessary.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer

Alain R. Thierry, Brice Pastor, Ekaterina Pisareva, Francois Ghiringhelli, Olivier Bouche, Christelle De La Fouchardiere, Julie Vanbockstael, Denis Smith, Eric Francois, Melanie Dos Santos, Damien Botsen, Stephen Ellis, Marianne Fonck, Thierry Andre, Emmanuel Guardiola, Faiza Khemissa, Benjamin Linot, J. Martin-Babau, Yves Rinaldi, Eric Assenat, Lea Clavel, Sophie Dominguez, Celine Gavoille, David Sefrioui, Veronica Pezzella, Caroline Mollevi, Marc Ychou, Thibault Mazard

Summary: This study found differences in tumor burden between patients diagnosed with mCRC before vs after the first COVID-19 lockdown in France. The findings suggest that colorectal cancer is a major area for intervention to minimize pandemic-associated delays in screening, diagnosis, and treatment.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Oncology

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers

William Jacot, Aurelie Maran-Gonzalez, Oceane Massol, Charlotte Sorbs, Caroline Mollevi, Severine Guiu, Florence Boissiere-Michot, Jeanne Ramos

Summary: The study evaluated HER2 expression and prognostic value in 296 patients with non-metastatic triple-negative breast cancer (TNBC). It was found that HER2 1+/2+ expression was associated with lower histological grade and molecular apocrine profile, with a subgroup of patients having worse long-term prognosis. The rare HER2 2+ TNBC subgroup showed worse relapse-free survival, emphasizing the need for dedicated evaluation for this group.

CANCERS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects

Fanny Leenhardt, Frederic Fiteni, Ludovic Gauthier, Marie Alexandre, Severine Guiu, Nelly Firmin, Stephane Pouderoux, Marie Viala, Gerald Lossaint, Chloe Gautier, Caroline Mollevi, Matthieu Gracia, Celine Gongora, Litaty Mbatchi, Alexandre Evrard, William Jacot

Summary: This study confirms the importance of therapeutic drug monitoring (TDM) in managing the safe use of Palbociclib, particularly in relation to hematological toxicity. The study also highlights the significance of characterizing co-treatments to limit the risk of drug-drug interactions (DDI) with oral-targeted therapies.

PHARMACEUTICS (2022)

Add to Collection

Article Oncology

Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer

Angelique Bobrie, Oceane Massol, Jeanne Ramos, Caroline Mollevi, Evelyne Lopez-Crapez, Nathalie Bonnefoy, Florence Boissiere-Michot, William Jacot

Summary: This study focused on the immune tumor microenvironment in triple-negative breast cancer (TNBC), specifically investigating the role of macrophages. The findings revealed that a subgroup of TNBCs characterized by CD206 expression in macrophages may have a better prognosis, suggesting potential therapeutic options for this immune TNBC subgroup.

CANCERS (2022)

Add to Collection

Article Medicine, Research & Experimental

A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment

Lindsay B. Alcaraz, Aude Mallavialle, Timothee David, Danielle Derocq, Frederic Delolme, Cindy Dieryckx, Caroline Mollevi, Florence Boissiere-Michot, Joelle Simony-Lafontaine, Stanislas Du Manoir, Pitter F. Huesgen, Christopher M. Overall, Sophie Tartare-Deckert, William Jacot, Thierry Chardes, Severine Guiu, Pascal Roger, Thomas Reinheckel, Catherine Moali, Emmanuelle Liaudet-Coopman

Summary: This study identified a novel crosstalk between proteases and matricellular proteins in the tumor microenvironment through limited SPARC proteolysis, revealing a novel targetable 9-kDa bioactive SPARC fragment for new TNBC treatments. The research paves the way for developing strategies to target bioactive fragments from matricellular proteins in TNBC.

THERANOSTICS (2021)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.